NEW YORK, July 25, 2018 /PRNewswire/ --

If you want a free Stock Review on AGEN, AIMT, AKBA, and ALDR sign up now at https://stocktraderreport.com/registration/. On Tuesday, key US indices were mixed as the NASDAQ Composite finished the trading session down 0.01%; the Dow Jones Industrial Average edged 0.79% higher; and the S&P 500 was up 0.48%. Before the US markets open this morning, StockTraderReport.com appraises these four Biotechnology equities: Agenus Inc. (NASDAQ:AGEN), Aimmune Therapeutics Inc. (NASDAQ:AIMT), Akebia Therapeutics Inc. (NASDAQ:AKBA), and Alder Biopharmaceuticals Inc. (NASDAQ:ALDR). All you have to do is sign up today for this free limited time offer by clicking the link below. https://stocktraderreport.com/registration/

Agenus 

USA -headquartered Agenus Inc.'s stock finished Tuesday's session 5.83% lower at $1.94. A total volume of 2.62 million shares was traded, which was above its three months average volume of 1.43 million shares. The stock is trading below its 50-day moving average by 30.38%. Furthermore, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system to fight cancer, have a Relative Strength Index (RSI) of 27.84.

On July 16 ^th, 2018, Agenus announced the appointment of I-O drug development experts into key leadership positions to advance multiple clinical programs and planned BLA filings by 2020. Dr. Sunil Gupta joins the Company as Vice President of Regulatory and Pharmacovigilance, and Dr. Anna Wijatyk joins as Vice President of Clinical Development. Get the full research report on AGEN for free by clicking below at: https://stocktraderreport.com/registration/?symbol=AGEN

Aimmune Therapeutics 

Shares in USA-based Aimmune Therapeutics Inc. ended at $29.72, up 0.71% from the last trading session. The stock recorded a trading volume of 407,249 shares. The Company's shares have gained 35.09% in the last twelve months. The stock is trading below its 50-day moving average by 0.80%. Moreover, shares of Aimmune Therapeutics, which develops and commercializes product candidates for the treatment of peanut and other food allergies, have an RSI of 53.01. To experience our free membership services anytime/ anywhere and access the free report on AIMT, click to register at: https://stocktraderreport.com/registration/?symbol=AIMT

Akebia Therapeutics 

USA -based Akebia Therapeutics Inc.'s stock ended yesterday's session 1.74% higher at $10.51 with a total trading volume of 540,772 shares, which was above its three months average volume of 532.94 thousand shares. The Company's shares have advanced 12.29% over the previous three months. The stock is trading above its 50-day moving average by 2.11%. Additionally, shares of Akebia Therapeutics, which focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor biology, have an RSI of 54.43.

On July 02 ^nd, 2018, Akebia Therapeutics (AKBA) announced that it granted six, newly-hired employees options to purchase an aggregate of 12,050 shares of its common stock on June 29 ^th, 2018, as inducements material to each such employee's entering into employment with AKBA. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). Join our big investor community at Stock Trader Report now and get your free report on AKBA at: https://stocktraderreport.com/registration/?symbol=AKBA

Alder Biopharmaceuticals 

On Tuesday, shares in USA-headquartered Alder Biopharmaceuticals Inc. recorded a trading volume of 740,547 shares. The stock finished the day 2.16% lower at $18.10. The Company's shares have advanced 38.70% in the previous three months, 52.10% over the last twelve months, and 58.08% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.10% and 29.69%, respectively. Furthermore, shares of Alder Biopharma, which operates as a clinical-stage biopharmaceutical company, have an RSI of 54.90.

On June 27 ^th, 2018, research firm Needham resumed its 'Buy' rating on the Company's stock, with a target price of $28 per share.

On June 29 ^th, 2018, Alder Biopharma announced new, one-year efficacy data from the PROMISE 1 Phase-3 clinical trial in patients with episodic migraine. The data demonstrate that patients experienced even further reductions in monthly migraine days following the third and fourth quarterly infusions of eptinezumab, the Company's lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide. Know more about ALDR in our free research coverage at: https://stocktraderreport.com/registration/?symbol=ALDR

--

Stock Trader Report: 

Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

STR has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stocktraderreport.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://stocktraderreport.com/privacy-policy/

CONTACT 
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stocktraderreport.com
Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Stock Trader Report